Italian Drug Maker Menarini Aims To Expand Into US and Japan

 
• By Sten Stovall
  
Generate a summary of this article
Listen to this article
Beta

The corporate licensing director at A. Menarini IFR tells Sten Stovall why and how Italy's largest drug maker plans to expand into the US and Japanese markets.

Giammario Piras

Italy's largest drug maker A. Menarini IFR hopes to penetrate the US market via the in-licensing of drugs in therapeutic areas such as oncology and cardiovascular, and perhaps by making an acquisition there, the group's corporate licensing director Giammario Piras says in a television interview, adding that entering Japan might prove harder to do but is nonetheless a priority. The group is also expanding its over-the-counter offerings in Asia.

A. Menarini IFR corporate licensing director Giammario Piras

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains